Key result
Cardiomyopathic hamsters show ~32% greater myocardial Tc-99m nitroimidazole uptake, suggesting hypoxia contributes to cardiomyopathy.
Why the study?
Does myocardial hypoxia contribute to the development of cardiomyopathy in a hamster model?
Population
Cardiomyopathic Syrian hamsters and control hamsters at age 10, 25, and 40 weeks (n=6 in each group)
Comparison
Injection of Tc-99m nitroimidazole and I-125… vs Control hamsters
Design
Preclinical
Authors
Loading...
Supports hypoxia in hamster cardiomyopathy progression; hypothesis-generating for human mechanisms and imaging.
Does myocardial hypoxia contribute to the development of cardiomyopathy in a hamster model?
Absolute Event Rate: 33.3% vs 25.2%
Myocardial hypoxia is present during the fibrotic and healing stages of cardiomyopathy in a hamster model, suggesting it contributes to disease progression.
Watanabe et al. (1997) studied Cardiomyopathy (n=36). Cardiomyopathic strain vs. Control hamsters was evaluated on Myocardial uptake of Tc-99m nitroimidazole at age 25 weeks. Cardiomyopathic hamsters had significantly greater myocardial uptake of Tc-99m nitroimidazole than controls at 25 weeks (33.3 vs 25.2 % g dose/g), suggesting hypoxia contributes to cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: